



ABN 82 010 975 612

Level 18, 101 Collins Street
Victoria 3000 Australia
Telephone: + 61 7 3088 7926
Facsimile: + 61 7 3394 4394
www.tbgbio.com

Receipt of R&D Tax Incentive Refund

Melbourne, Australia, 2 February 2017. TBG Diagnostics Limited ("TBG" or "the Company") (ASX: TDL, OTC: TDLAF) is pleased to advise that it has received a refund from the Australian Taxation Office of \$1,012,341 pursuant to the Federal Government's R&D Tax Incentive Scheme following the lodgement of its 2015/16 financial year income tax return.

The R&D Tax Incentive is an Australian Government program under which tax loss companies with a group turnover of less than \$20 million can receive cash refunds for 45% of eligible expenditure on research and development.

About TBG Diagnostics

TBG Diagnostics is a global molecular diagnostic (MDx) company operating in the IVD (in vitro diagnostics) industry. TBG is focused on the development, manufacture and marketing of molecular diagnostic kits, instruments and services

TBG Diagnostics is an established brand with a strong presence in the Asian market. From its plant in Xiamen, China it develops and manufactures:

- Nucleic Acid Test (NAT) products
- HLA typing reagents based on NAT technologies
- Automation systems for NAT operations
- IVD-related NAT kits and services

Products distributed to more than 22 countries. Major hospital and laboratory clients in USA, Taiwan, Germany, Portugal, China, Hong Kong and Singapore. Operating in the rapidly growing IVD market - US\$53 billion in 2013 and expected to reach US\$74.7 billion by 2020.

Targeting further growth in China - fastest growing MDx market at CAGR of 27.9%. Extensive research and development pipeline targeting products for oncology, infectious diseases, transplants, transfusions, pharmacogenetics, autoimmune diseases and genetic diseases

For more information:

Justyn Stedwell
Company Secretary
+61 7 3088 7926
+61 7 3394 4394